Genus plc (GNS) is a leading biotechnology business based in the UK. It opened the day at 4320p after a previous close of 4212p. During the day the price has varied from a low of 4156p to a high of 4320p. The latest price was 4196p (25 minute delay). Genus is listed on the London Stock Exchange (LSE) and employs 3,100 staff. All prices are listed in pence sterling.
Since the stock market crash in March caused by coronavirus, Genus's share price has had significant positive movement.
Its last market close was 4150p, which is 20.63% up on its pre-crash value of 3294p and 68.38% up on the lowest point reached during the March crash when the shares fell as low as 2464.6p.
If you had bought £1,000 worth of Genus shares at the start of February 2020, those shares would have been worth £927.34 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth £1,347.51.
|52-week range||2532.1521p - 4485.0146p|
|50-day moving average||4152.1177p|
|200-day moving average||3784.2395p|
|Wall St. target price||2332.5p|
|Dividend yield||0.29p (0.7%)|
|Earnings per share (TTM)||61.9p|
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|1 week (2021-01-11)||-4.24%|
|1 month (2020-12-18)||4196|
|3 months (2020-10-19)||1.11%|
|6 months (2020-07-17)||19.75%|
|1 year (2020-01-17)||36.06%|
|2 years (2019-01-18)||89.69%|
|3 years (2018-01-18)||65.98%|
|5 years (2016-01-18)||201.44%|
Valuing Genus stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Genus's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Genus's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 67x. In other words, Genus shares trade at around 67x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the FTSE 250 at the end of September 2019 (19.71). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Genus's EBITDA (earnings before interest, taxes, depreciation and amortisation) is £73.2 million.
The EBITDA is a measure of a Genus's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||£551.4 million|
|Operating margin TTM||9.18%|
|Gross profit TTM||£211.6 million|
|Return on assets TTM||3.78%|
|Return on equity TTM||8.22%|
|Market capitalisation||£2.7 billion|
TTM: trailing 12 months
Dividend payout ratio: 4619.05% of net profits
Recently Genus has paid out, on average, around 4619.05% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.7% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Genus shareholders could enjoy a 0.7% return on their shares, in the form of dividend payments. In Genus's case, that would currently equate to about 0.29p per share.
Genus's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
The latest dividend was paid out to all shareholders who bought their shares by 19 November 2020 (the "ex-dividend date").
Over the last 12 months, Genus's shares have ranged in value from as little as 2532.1521p up to 4485.0146p. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (LSE average) beta is 1, while Genus's is 0.2269. This would suggest that Genus's shares are less volatile than average (for this exchange).
Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Research and Development. It sells sows, boars, and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands. In addition, it offers semen sexing, in vitro fertilization, reproductive, and other technical services to farmers. Genus plc has a strategic porcine collaboration with Beijing Capital Agribusiness Co. Ltd to research, develop, register, and market porcine reproductive and respiratory syndrome virus resistant pigs. The company was incorporated in 1994 and is based in Basingstoke, the United Kingdom.
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.
Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.
Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.
Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.
Ever wondered how to buy shares in Van Elle Holdings? We explain how and compare a range of providers that can give you access to many brands, including Van Elle Holdings.
Ever wondered how to buy shares in ULS Technology? We explain how and compare a range of providers that can give you access to many brands, including ULS Technology.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.